ClinicalTrials.gg
TerminatedNCT02331875Updated Jan 4, 2017

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

A Phase 1/2 interventional study of IPH2201 and Standard Surgery in Squamous Cell Carcinoma of the Oral Cavity, sponsored by Innate Pharma. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-04.

Sponsored by Innate Pharma · Phase 1/2, Interventional, and Treatment

Why this study was terminated
lack of recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain — 36 open to participants now, 70 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Spain.

Enrollment
159th of 161
3 · median 160
Started
2014
with 4 others
Phase 1/2
33 of 167
11 open now
Registered
20th of 167
by date

Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, this one is the 159th largest by enrollment of the 161 interventional ones that give a count, is one of 5 that started in 2014, is one of 33 in phase 1/2, and was the 20th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

36 of the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, or all of them as a file.
02

Study summary

The primary objective of this open label Phase Ib/II trial is to evaluate the clinical and pharmacological activity of IPH2201 as a single-agent in treatment-naïve pre-operative patients with operable Squamous Cell Carcinoma of the Oral Cavity .

43 patients are planned to be enrolled. The first 6 patients will receive IPH2201 at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4. Standard loco-regional treatment with surgery followed by adjuvant therapy will be initiated after the last administration of IPH2201.

03

Conditions studied

  • Squamous Cell Carcinoma of the Oral Cavity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, primary, previously untreated, resectable squamous cell carcinoma of the oral cavity considered clinically and radiologically as intermediate or high risk, classified II ( with large (≥ 3 cm and ≤ 4cm) cT2cN0cM0 tumors or any cT2cN0cM0 tumor invading neighboring structures) III or IVa according to the American Joint Committee on Cancer
  • Adequate liver and renal function

Exclusion criteria

Exclusion criteria:

  • Other
  • Abnormal cardiac status
  • disease
  • Serious concurrent uncontrolled medical disorder
  • Systemic treatment with or other agents within 30 days prior to IPH2201 first administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    single arm

    IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy

    Drug: IPH2201 · Procedure: Standard Surgery · Radiation: Postsurgical Adjuvant Therapy

Interventions

  • The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.

  • ProcedureStandard Surgery

    After the end of treatment with IPH2201, according to standard recommendations in the relevant country .

  • RadiationPostsurgical Adjuvant Therapy

    After the standard surgery, according to standard recommendations in the relevant country

06

What researchers measure

Primary outcomes

  1. best objective response rate

    Time frame: 8 weeks

07

Study locations

3 sites
  • Charité University Medicine Berlin
    Berlin, 13353, Germany
  • Instituto Catalan de Oncologia - L'Hospitalet
    L'Hospitalet de Llobregat Barcelona, 08907, Spain
  • Hospital Universitario La Paz
    Madrid, 28047, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2015
First posted
Jan 6, 2015
Start
Dec 2014
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Last update
Jan 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02331875
Lead sponsor
Innate Pharma
Responsible party
Sponsor
First posted
Jan 6, 2015
Start date
Dec 2014
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Jan 4, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Monalizumab

Start the discussion